Live price temporarily unavailable.
Neurocrine Biosciences (NBIX) is a Health Care company in the Russell 1000. Latest news and coverage below.
Neurocrine Biosciences revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $15.0M | $161.6M | $451.2M | $788.1M | $1.05B | $1.13B | $1.49B | $1.89B | $2.36B | $2.86B |
| Growth (year over year) | −24.1% | +977.5% | +179.2% | +74.7% | +32.7% | +8.4% | +31.3% | +26.8% | +24.8% | +21.4% |
| Gross profit | $15.0M | $160.4M | $446.3M | — | $1.04B | $1.12B | $1.47B | $1.85B | $2.32B | $2.81B |
| Gross margin | 100.0% | 99.2% | 98.9% | — | 99.0% | 98.7% | 98.4% | 97.9% | 98.6% | 98.2% |
| Operating income | −$147.4M | −$131.4M | $36.8M | $72.3M | $163.0M | $102.5M | $249.0M | $250.9M | $570.5M | $619.1M |
| Operating margin | −982.5% | −81.3% | 8.2% | 9.2% | 15.6% | 9.0% | 16.7% | 13.3% | 24.2% | 21.6% |
| Net income | −$141.1M | −$142.5M | $21.1M | $37.0M | $407.3M | $89.6M | $154.5M | $249.7M | $341.3M | $478.6M |
| Net margin | −940.6% | −88.2% | 4.7% | 4.7% | 38.9% | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% |
| EPS (diluted) | −$1.63 | −$1.62 | $0.22 | $0.39 | $4.16 | $0.92 | $1.56 | $2.47 | $3.29 | $4.67 |
| Balance sheet | ||||||||||
| Cash and equivalents | $83.3M | $254.7M | $141.7M | $112.3M | $187.1M | $340.8M | $262.9M | $251.1M | $233.0M | $713.0M |
| Total assets | $365.1M | $817.6M | $993.2M | $1.31B | $1.73B | $2.07B | $2.37B | $3.25B | $3.72B | $4.63B |
| Total liabilities | $50.2M | $445.5M | $512.4M | $669.1M | $608.5M | $698.5M | $660.9M | $1.02B | $1.13B | $1.38B |
| Shareholders' equity | $314.9M | $372.2M | $480.8M | $636.9M | $1.13B | $1.37B | $1.71B | $2.23B | $2.59B | $3.25B |
| Cash flow | ||||||||||
| Operating cash flow | −$106.2M | −$94.3M | $101.4M | $147.0M | $228.5M | $256.5M | $339.4M | $389.9M | $595.4M | $782.7M |
| Capital expenditure | $4.11M | $6.94M | $24.8M | $14.7M | $10.9M | $23.4M | $16.5M | $28.3M | $38.2M | $34.0M |
| Free cash flow | −$110.3M | −$101.3M | $76.6M | $132.3M | $217.6M | $233.1M | $322.9M | $361.6M | $557.2M | $748.7M |
| Share buybacks | — | — | — | — | — | — | $0 | $0 | $300.0M | $167.7M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $622.1M | $627.7M | $572.6M | $687.5M | $794.9M | $805.5M | $814.5M | $959.0M |
| Growth (year over year) | +24.7% | +21.8% | +11.1% | +16.5% | +27.8% | +28.3% | +42.2% | +39.5% |
| Gross profit | $614.1M | $618.4M | $563.4M | $676.2M | $780.9M | $787.9M | $800.7M | $935.8M |
| Gross margin | 98.7% | 98.5% | 98.4% | 98.4% | 98.2% | 97.8% | 98.3% | 97.6% |
| Operating income | $183.8M | $142.0M | $23.6M | $145.6M | $239.0M | $210.9M | $193.4M | $151.5M |
| Operating margin | 29.5% | 22.6% | 4.1% | 21.2% | 30.1% | 26.2% | 23.7% | 15.8% |
| Net income | $129.8M | $103.1M | $7.90M | $107.5M | $209.5M | $153.7M | $197.9M | $144.4M |
| Net margin | 20.9% | 16.4% | 1.4% | 15.6% | 26.4% | 19.1% | 24.3% | 15.1% |
| EPS (diluted) | $1.24 | $1.00 | $0.08 | $1.06 | $2.04 | $1.49 | $1.91 | $1.39 |
| Balance sheet | ||||||||
| Cash and equivalents | $349.1M | $233.0M | $194.1M | $264.0M | $340.2M | $713.0M | $266.5M | $332.4M |
| Total assets | $3.54B | $3.72B | $3.69B | $3.89B | $4.27B | $4.63B | $4.91B | $5.36B |
| Total liabilities | $816.1M | $1.13B | $1.15B | $1.20B | $1.26B | $1.38B | $1.50B | $1.67B |
| Shareholders' equity | $2.72B | $2.59B | $2.54B | $2.69B | $3.00B | $3.25B | $3.41B | $3.69B |
| Cash flow | ||||||||
| Operating cash flow | $158.0M | $242.5M | $64.8M | $102.0M | $227.5M | $388.4M | $145.8M | $136.4M |
| Capital expenditure | $8.10M | $7.30M | $10.7M | $12.5M | $13.2M | −$2.40M | $9.10M | $7.80M |
| Free cash flow | $149.9M | $235.2M | $54.1M | $89.5M | $214.3M | $390.8M | $136.7M | $128.6M |
| Share buybacks | $0 | $300.0M | $150.0M | $17.7M | $0 | $0 | $54.0M | $12.0M |
From Neurocrine Biosciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
Source: Wikipedia — Neurocrine Biosciences
- Headquarters
- San Diego, California From SEC filings, Oct 2026
Recent News
No recent news mentioning Neurocrine Biosciences in our feed yet.
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International